News about "Sandoz"

Sandoz Partners with Elawan Energy to Decarbonize European Operations

Sandoz has signed a 10-year virtual Power Purchase Agreement (PPA) with Elawan Energy to co-develop 150 MW of new solar projects in Valladolid, Castilla y Leon, Spain.

Sandoz | 12/08/2025 | By Dineshwori

Sandoz Reports Strong H1 2025 Results, Accelerated Growth in Biosimilars and Generics

Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion. Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.

Sandoz | 07/08/2025 | By Dineshwori |  154

Sandoz Reports Strong H1 2025 Results, Accelerated Growth in Biosimilars and Generics

Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion. Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.

Sandoz | 07/08/2025 | By Dineshwori |  154

Sandoz to Acquire Just-Evotec Biologics in USD 300 Million Deal

Sandoz has signed a non-binding term sheet with Evotec SE, paving the way for the potential acquisition of Just–Evotec Biologics EU SAS for approximately USD 300 million.

Sandoz | 30/07/2025 | By Dineshwori |  108

FDA Drug Approvals Fall in 2024, But Small Pharma Fuels Innovation Surge

The US Food and Drug Administration (FDA) approved 127 innovator and biosimilar drugs in 2024, marking a decline from the 149 approvals recorded in 2023, according to a report by leading data and analytics firm GlobalData.

Sandoz | 19/07/2025 | By Dineshwori |  150

Pharma Leaders Back UK Life Sciences Strategy, But ABPI Warns of Medicines Investment Gap

Pharmaceutical and medical technology leaders, including GSK, Sandoz, Accord Healthcare, Becton Dickinson, and Celltrion have welcomed the UK government’s new Life Sciences Sector Plan, recently unveiled as part of its flagship Industrial Strategy.

Sandoz | 19/07/2025 | By Dineshwori

Biologics and Biosimilars Market: APAC Poised for Rapid Growth Driven by Rising Investments and Patient Pool

The global biologics and biosimilars market is expected to reach approximately USD 600 billion by 2032, expanding at a compound annual growth rate (CAGR) of around 6.33 percent during the forecast period.

Sandoz, | 15/07/2025 | By Dineshwori

Sandoz Begins Construction Of USD 440 Million Biosimilars Production Facility In Slovenia

Sandoz is constructing a new facility in Slovenia to strengthen its European biosimilar hub and expand its global market presence.

Sandoz | 10/07/2025 | By Dineshwori |  178

Alembic Pharma Gets USFDA Final Approval for Nelarabine Injection

Alembic Pharmaceuticals has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nelarabine Injection, 250 mg/50 mL (5 mg/mL) (Single-Dose Vial).

Sandoz | 05/08/2024 | By Aishwarya |  418

Sandoz Acquires Astellas' Antifungal Agent Mycamine

The company stated "Through this acquisition of the leading global echinocandin, one of three major antifungal classes, Sandoz significantly reinforces its global hospital offering and leading anti-infectives portfolio.

Sandoz | 29/08/2023 | By Manvi |  495